
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corp's stock is positively influenced by the anticipated growth in its MACI product, with projected volume increasing in the low-to-mid teens alongside an annual average selling price (ASP) increase of approximately 300 to 500 basis points. This growth trajectory is supported by estimates indicating a year-over-year revenue increase for MACI of around 21.2% in fiscal year 2026, fueled by a favorable combination of volume and pricing dynamics. Furthermore, positive financial performance is evident as 4Q revenue is expected to reach $84.8 million, representing a notable 26% quarter-over-quarter growth.
Bears say
Vericel Corp faces a negative outlook primarily due to revised revenue expectations for its MACI product, which have been lowered by approximately 200 basis points for fiscal years 2026 and 2027. There are significant risks associated with slower adoption rates for MACI and MACI Arthro, as well as challenges in burn care sales and potential disruptions from sales force expansion. Additionally, any failure to meet top-line revenue expectations may result in the company's shares declining to historically low valuation levels.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares